{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:13:47Z","timestamp":1777490027227,"version":"3.51.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40271-025-00797-9","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T05:14:15Z","timestamp":1767762855000},"page":"449-463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patient Preferences for Neuromyelitis Optica Spectrum Disorder (NMOSD) Treatments: Results from a Discrete Choice Experiment Study in the USA"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1668-4753","authenticated-orcid":false,"given":"Justin R.","family":"Abbatemarco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0366-4078","authenticated-orcid":false,"given":"Adrian","family":"Kielhorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey C.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7221-6365","authenticated-orcid":false,"given":"Sami","family":"Fam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-5677","authenticated-orcid":false,"given":"Kelley","family":"Myers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7810-3411","authenticated-orcid":false,"given":"Christine M.","family":"Poulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5359-6686","authenticated-orcid":false,"given":"Devon S.","family":"Conway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"issue":"7","key":"797_CR1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMra1904655","volume":"387","author":"DM Wingerchuk","year":"2022","unstructured":"Wingerchuk DM, Lucchinetti CF. Neuromyelitis optica spectrum disorder. N Engl J Med. 2022;387(7):631\u20139. https:\/\/doi.org\/10.1056\/NEJMra1904655.","journal-title":"N Engl J Med"},{"key":"797_CR2","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fneur.2020.00501","volume":"11","author":"JY Hor","year":"2020","unstructured":"Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol. 2020;11:501. https:\/\/doi.org\/10.3389\/fneur.2020.00501.","journal-title":"Front Neurol"},{"key":"797_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/13524585251328554","author":"A Lee","year":"2025","unstructured":"Lee A, Iordanova RT, Smith JB, Li BH, Schwarzmann KB, Alsalek S, et al. Incidence and prevalence of neuromyelitis optica spectrum disorder in a contemporary, multi-ethnic cohort. Mult Scler. 2025. https:\/\/doi.org\/10.1177\/13524585251328554.","journal-title":"Mult Scler"},{"issue":"1","key":"797_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0718-0","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm. 2016;13(1):280. https:\/\/doi.org\/10.1186\/s12974-016-0718-0.","journal-title":"J Neuroinflamm"},{"key":"797_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-9-14","volume":"9","author":"S Jarius","year":"2012","unstructured":"Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflamm. 2012;9:14. https:\/\/doi.org\/10.1186\/1742-2094-9-14.","journal-title":"J Neuroinflamm"},{"issue":"9","key":"797_CR6","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","volume":"69","author":"MA Mealy","year":"2012","unstructured":"Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012;69(9):1176\u201380. https:\/\/doi.org\/10.1001\/archneurol.2012.314.","journal-title":"Arch Neurol"},{"issue":"10","key":"797_CR7","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","volume":"264","author":"SHM Hamid","year":"2017","unstructured":"Hamid SHM, Whittam D, Mutch K, Linaker S, Solomon T, Das K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017;264(10):2088\u201394. https:\/\/doi.org\/10.1007\/s00415-017-8596-7.","journal-title":"J Neurol"},{"issue":"14","key":"797_CR8","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1177\/1352458517735191","volume":"24","author":"M Sep\u00falveda","year":"2018","unstructured":"Sep\u00falveda M, Aldea M, Escudero D, Llufriu S, Arrambide G, Otero-Romero S, et al. Epidemiology of NMOSD in Catalonia: influence of the new 2015 criteria in incidence and prevalence estimates. Mult Scler. 2018;24(14):1843\u201351. https:\/\/doi.org\/10.1177\/1352458517735191.","journal-title":"Mult Scler"},{"issue":"5","key":"797_CR9","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000583","volume":"6","author":"LJ Cook","year":"2019","unstructured":"Cook LJ, Rose JW, Alvey JS, Jolley AM, Kuhn R, Marron B, et al. Collaborative international research in clinical and longitudinal experience study in NMOSD. Neurol Neuroimmunol Neuroinflamm. 2019;6(5):e583. https:\/\/doi.org\/10.1212\/NXI.0000000000000583.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"19","key":"797_CR10","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1212\/WNL.0000000000004611","volume":"89","author":"H Houzen","year":"2017","unstructured":"Houzen H, Kondo K, Niino M, Horiuchi K, Takahashi T, Nakashima I, et al. Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan. Neurology. 2017;89(19):1995\u20132001. https:\/\/doi.org\/10.1212\/WNL.0000000000004611.","journal-title":"Neurology"},{"issue":"2","key":"797_CR11","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/ene.14079","volume":"27","author":"V Papp","year":"2020","unstructured":"Papp V, Iljicsov A, Rajda C, Magyari M, Koch-Henriksen N, Petersen T, et al. A population-based epidemiological study of neuromyelitis optica spectrum disorder in Hungary. Eur J Neurol. 2020;27(2):308\u201317. https:\/\/doi.org\/10.1111\/ene.14079.","journal-title":"Eur J Neurol"},{"issue":"5","key":"797_CR12","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/wnl.53.5.1107","volume":"53","author":"DM Wingerchuk","year":"1999","unstructured":"Wingerchuk DM, Hogancamp WF, O\u2019Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology. 1999;53(5):1107\u201314. https:\/\/doi.org\/10.1212\/wnl.53.5.1107.","journal-title":"Neurology"},{"issue":"1","key":"797_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","volume":"271","author":"T K\u00fcmpfel","year":"2024","unstructured":"K\u00fcmpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, H\u00e4ussler V, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)\u2014revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management. J Neurol. 2024;271(1):141\u201376. https:\/\/doi.org\/10.1007\/s00415-023-11910-z.","journal-title":"J Neurol"},{"key":"797_CR14","unstructured":"Ultomiris (ravulizumab-cwvz) [prescribing information]. Boston, MA: Alexion Pharmaceuticals, Inc.; 2025."},{"key":"797_CR15","unstructured":"Soliris (eculizumab) [prescribing information]. Boston, MA: Alexion Pharmaceuticals, Inc.; 2025."},{"key":"797_CR16","unstructured":"Uplizna (inebilizumab-cdon) [prescribing information]. Deerfield, IL: Horizon Therapeutics USA, Inc.; 2025."},{"key":"797_CR17","unstructured":"Enspryng (satralizumab-mwge) [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2022."},{"issue":"6","key":"797_CR18","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/ana.26626","volume":"93","author":"SJ Pittock","year":"2023","unstructured":"Pittock SJ, Barnett M, Bennett JL, Berthele A, de Seze J, Levy M, et al. Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann Neurol. 2023;93(6):1053\u201368. https:\/\/doi.org\/10.1002\/ana.26626.","journal-title":"Ann Neurol"},{"issue":"7","key":"797_CR19","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1900866.","journal-title":"N Engl J Med"},{"issue":"3","key":"797_CR20","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1177\/13524585211038291","volume":"28","author":"SJ Pittock","year":"2022","unstructured":"Pittock SJ, Fujihara K, Palace J, Berthele A, Kim HJ, Oreja-Guevara C, et al. Eculizumab monotherapy for NMOSD: data from PREVENT and its open-label extension. Mult Scler. 2022;28(3):480\u20136. https:\/\/doi.org\/10.1177\/13524585211038291.","journal-title":"Mult Scler"},{"issue":"6","key":"797_CR21","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/ana.26049","volume":"89","author":"DM Wingerchuk","year":"2021","unstructured":"Wingerchuk DM, Fujihara K, Palace J, Berthele A, Levy M, Kim HJ, et al. Long-term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD. Ann Neurol. 2021;89(6):1088\u201398. https:\/\/doi.org\/10.1002\/ana.26049.","journal-title":"Ann Neurol"},{"issue":"6","key":"797_CR22","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S1474-4422(24)00077-2","volume":"23","author":"BAC Cree","year":"2024","unstructured":"Cree BAC, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, et al. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial. Lancet Neurol. 2024;23(6):588\u2013602. https:\/\/doi.org\/10.1016\/S1474-4422(24)00077-2.","journal-title":"Lancet Neurol"},{"issue":"13","key":"797_CR23","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1177\/1352458521988926","volume":"27","author":"BA Cree","year":"2021","unstructured":"Cree BA, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, et al. Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. Mult Scler. 2021;27(13):2052\u201361. https:\/\/doi.org\/10.1177\/1352458521988926.","journal-title":"Mult Scler"},{"issue":"10206","key":"797_CR24","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet. 2019;394(10206):1352\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(19)31817-3.","journal-title":"Lancet"},{"issue":"5","key":"797_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402\u201312. https:\/\/doi.org\/10.1016\/S1474-4422(20)30078-8.","journal-title":"Lancet Neurol"},{"issue":"22","key":"797_CR26","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1901747.","journal-title":"N Engl J Med"},{"key":"797_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104025","volume":"66","author":"T Yamamura","year":"2022","unstructured":"Yamamura T, Weinshenker B, Yeaman MR, De Seze J, Patti F, Lobo P, et al. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult Scler Relat Disord. 2022;66:104025. https:\/\/doi.org\/10.1016\/j.msard.2022.104025.","journal-title":"Mult Scler Relat Disord."},{"issue":"1","key":"797_CR28","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200071","volume":"10","author":"I Kleiter","year":"2023","unstructured":"Kleiter I, Traboulsee A, Palace J, Yamamura T, Fujihara K, Saiz A, et al. Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm. 2023;10(1):e200071. https:\/\/doi.org\/10.1212\/NXI.0000000000200071.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"797_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104400","volume":"68","author":"J Peters","year":"2022","unstructured":"Peters J, Longbrake EE. Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease. Mult Scler Relat Disord. 2022;68:104400. https:\/\/doi.org\/10.1016\/j.msard.2022.104400.","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"797_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40120-024-00597-7","volume":"13","author":"SL Clardy","year":"2024","unstructured":"Clardy SL, Pittock SJ, Aktas O, Nakahara J, Isobe N, Centonze D, et al. Network meta-analysis of ravulizumab and alternative interventions for the treatment of neuromyelitis optica spectrum disorder. Neurol Ther. 2024;13(3):535\u201349. https:\/\/doi.org\/10.1007\/s40120-024-00597-7.","journal-title":"Neurol Ther"},{"key":"797_CR31","unstructured":"FDA. Focus area: patient and consumer preferences and perspectives. Updated 9 June 2022. https:\/\/www.fda.gov\/science-research\/focus-areas-regulatory-science-report\/focus-area-patient-and-consumer-preferences-and-perspectives. Accessed 17 Dec 2024."},{"issue":"7","key":"797_CR32","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.drudis.2019.05.001","volume":"24","author":"V Soekhai","year":"2019","unstructured":"Soekhai V, Whichello C, Levitan B, Veldwijk J, Pinto CA, Donkers B, et al. Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. Drug Discov Today. 2019;24(7):1324\u201331. https:\/\/doi.org\/10.1016\/j.drudis.2019.05.001.","journal-title":"Drug Discov Today"},{"issue":"4","key":"797_CR33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/hec.729","volume":"12","author":"F Carlsson","year":"2003","unstructured":"Carlsson F, Martinsson P. Design techniques for stated preference methods in health economics. Health Econ. 2003;12(4):281\u201394. https:\/\/doi.org\/10.1002\/hec.729.","journal-title":"Health Econ"},{"key":"797_CR34","unstructured":"Hole AR. DCREATE: Stata module to create efficient designs for discrete choice experiments (revised 25 August 2017). Boston College Department of Economics: statistical software components S458059; 2015."},{"issue":"4","key":"797_CR35","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1177\/002224379403100408","volume":"31","author":"WF Kuhfeld","year":"1994","unstructured":"Kuhfeld WF, Tobias RD, Garratt M. Efficient experimental design with marketing research applications. J Mark Res. 1994;31(4):545\u201357. https:\/\/doi.org\/10.1177\/002224379403100408.","journal-title":"J Mark Res"},{"issue":"4","key":"797_CR36","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1509\/jmkr.38.4.430.18904","volume":"38","author":"Z S\u00e1ndor","year":"2001","unstructured":"S\u00e1ndor Z, Wedel M. Designing conjoint choice experiments using managers\u2019 prior beliefs. J Mark Res. 2001;38(4):430\u201344. https:\/\/doi.org\/10.1509\/jmkr.38.4.430.18904.","journal-title":"J Mark Res"},{"issue":"4","key":"797_CR37","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JF Bridges","year":"2011","unstructured":"Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403\u201313. https:\/\/doi.org\/10.1016\/j.jval.2010.11.013.","journal-title":"Value Health"},{"issue":"4","key":"797_CR38","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber AB, Gonzalez JM, Groothuis-Oudshoorn CG, Prior T, Marshall DA, Cunningham C, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health. 2016;19(4):300\u201315. https:\/\/doi.org\/10.1016\/j.jval.2016.04.004.","journal-title":"Value Health"},{"issue":"1","key":"797_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"16","author":"FR Johnson","year":"2013","unstructured":"Johnson FR, Lancsar E, Marshall D, Kilambi V, Muhlbacher A, Regier DA, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013;16(1):3\u201313. https:\/\/doi.org\/10.1016\/j.jval.2012.08.2223.","journal-title":"Value Health"},{"issue":"10","key":"797_CR40","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1007\/s00464-014-4044-2","volume":"29","author":"MP Ho","year":"2015","unstructured":"Ho MP, Gonzalez JM, Lerner HP, Neuland CY, Whang JM, McMurry-Heath M, et al. Incorporating patient-preference evidence into regulatory decision making. Surg Endosc. 2015;29(10):2984\u201393. https:\/\/doi.org\/10.1007\/s00464-014-4044-2.","journal-title":"Surg Endosc"},{"issue":"4","key":"797_CR41","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s12325-025-03140-8","volume":"42","author":"J Yu","year":"2025","unstructured":"Yu J, Kielhorn A, Murdoch J, Martin M, Martin E, McNeil-Posey K, et al. Characterizing patient diversity via healthcare access determinants: a new approach for measuring improvements in clinical trial diversity in the United States. Adv Ther. 2025;42(4):1965\u201378. https:\/\/doi.org\/10.1007\/s12325-025-03140-8.","journal-title":"Adv Ther"},{"key":"797_CR42","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jocm.2015.09.001","volume":"16","author":"J-C Yang","year":"2015","unstructured":"Yang J-C, Johnson FR, Kilambi V, Mohamed AF. Sample size and utility-difference precision in discrete-choice experiments: a meta-simulation approach. J Choice Modelling. 2015;16:50\u20137. https:\/\/doi.org\/10.1016\/j.jocm.2015.09.001.","journal-title":"J Choice Modelling"},{"issue":"4","key":"797_CR43","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2165\/11539650-000000000-00000","volume":"3","author":"D Marshall","year":"2010","unstructured":"Marshall D, Bridges JF, Hauber B, Cameron R, Donnalley L, Fyie K, et al. Conjoint analysis applications in health\u2014how are studies being designed and reported?: an update on current practice in the published literature between 2005 and 2008. Patient Patient-Cent Outcomes Res. 2010;3(4):249\u201356. https:\/\/doi.org\/10.2165\/11539650-000000000-00000.","journal-title":"Patient Patient-Cent Outcomes Res"},{"issue":"2","key":"797_CR44","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40273-018-0734-2","volume":"37","author":"V Soekhai","year":"2019","unstructured":"Soekhai V, de Bekker-Grob EW, Ellis AR, Vass CM. Discrete choice experiments in health economics: past, present and future. Pharmacoeconomics. 2019;37(2):201\u201326. https:\/\/doi.org\/10.1007\/s40273-018-0734-2.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"797_CR45","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/1099-1255(200009\/10)15:5<447::AID-JAE570>3.0.CO;2-1","volume":"15","author":"D McFadden","year":"2000","unstructured":"McFadden D, Train K. Mixed MNL models for discrete response. J Appl Econ. 2000;15(5):447\u201370. https:\/\/doi.org\/10.1002\/1099-1255(200009\/10)15:5%3c447::AID-JAE570%3e3.0.CO;2-1.","journal-title":"J Appl Econ"},{"key":"797_CR46","volume-title":"Applications of simulation methods in environmental and resource economics the economics of non-market goods and resources. 6","author":"K Train","year":"2005","unstructured":"Train K, Sonnier G. Mixed logit with bounded distributions of correlated partworths. In: Scarpa R, Alberini A, editors. Applications of simulation methods in environmental and resource economics the economics of non-market goods and resources. 6. Dordrecht: Springer; 2005."},{"key":"797_CR47","volume-title":"Discrete choice methods with simulation","author":"K Train","year":"2009","unstructured":"Train K. Discrete choice methods with simulation. 2nd ed. New York: Cambridge University Press; 2009.","edition":"2"},{"key":"797_CR48","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9781316136232","volume-title":"Applied choice analysis","author":"DA Hensher","year":"2015","unstructured":"Hensher DA, Rose JM, Greene WH. Applied choice analysis. 2nd ed. Cambridge: Cambridge University Press; 2015.","edition":"2"},{"key":"797_CR49","volume-title":"Econometric analysis","author":"WH Greene","year":"2012","unstructured":"Greene WH. Econometric analysis. 7th ed. Boston: Pearson Education; 2012.","edition":"7"},{"issue":"4","key":"797_CR50","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/bmjebm-2022-112068","volume":"28","author":"VM Montori","year":"2023","unstructured":"Montori VM, Ruissen MM, Hargraves IG, Brito JP, Kunneman M. Shared decision-making as a method of care. BMJ Evid Based Med. 2023;28(4):213\u20137. https:\/\/doi.org\/10.1136\/bmjebm-2022-112068.","journal-title":"BMJ Evid Based Med"},{"issue":"1","key":"797_CR51","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.122.008997","volume":"16","author":"DE Kandzari","year":"2023","unstructured":"Kandzari DE, Weber MA, Poulos C, Coulter J, Cohen SA, DeBruin V, et al. Patient preferences for pharmaceutical and device-based treatments for uncontrolled hypertension: discrete choice experiment. Circ Cardiovasc Qual Outcomes. 2023;16(1):e008997. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.122.008997.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"797_CR52","doi-asserted-by":"publisher","DOI":"10.1177\/20552173221150370","volume":"9","author":"T Tervonen","year":"2023","unstructured":"Tervonen T, Fox RJ, Brooks A, Sidorenko T, Boyanova N, Levitan B, et al. Treatment preferences in relation to fatigue of patients with relapsing multiple sclerosis: a discrete choice experiment. Mult Scler J Exp Transl Clin. 2023;9(1):20552173221150370. https:\/\/doi.org\/10.1177\/20552173221150370.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"9","key":"797_CR53","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1136\/thoraxjnl-2019-213974","volume":"75","author":"T Tervonen","year":"2020","unstructured":"Tervonen T, Hawken N, Hanania NA, Martinez FJ, Heidenreich S, Gilbert I. Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment. Thorax. 2020;75(9):735\u201343. https:\/\/doi.org\/10.1136\/thoraxjnl-2019-213974.","journal-title":"Thorax"},{"issue":"1","key":"797_CR54","doi-asserted-by":"publisher","first-page":"1800222","DOI":"10.1183\/13993003.00222-2018","volume":"52","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Morgan RL, Alonso-Coello P, Wiercioch W, Bala MM, Jaeschke RR, et al. A systematic review of how patients value COPD outcomes. Eur Respir J. 2018;52(1):1800222. https:\/\/doi.org\/10.1183\/13993003.00222-2018.","journal-title":"Eur Respir J"},{"issue":"1","key":"797_CR55","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.reseneeco.2010.01.006","volume":"33","author":"JS Nielsen","year":"2011","unstructured":"Nielsen JS. Use of the internet for willingness-to-pay surveys: a comparison of face-to-face and web-based interviews. Resour Energy Econ. 2011;33(1):119\u201329. https:\/\/doi.org\/10.1016\/j.reseneeco.2010.01.006.","journal-title":"Resour Energy Econ"},{"issue":"3-4","key":"797_CR56","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ecolecon.2007.02.005","volume":"62","author":"C Marta-Pedroso","year":"2007","unstructured":"Marta-Pedroso C, Freitas H, Domingos T. Testing for the survey mode effect on contingent valuation data quality: a case study of web based versus in-person interviews. Ecol Econ. 2007;62(3\u20134):388\u201398. https:\/\/doi.org\/10.1016\/j.ecolecon.2007.02.005.","journal-title":"Ecol Econ"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-025-00797-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-025-00797-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-025-00797-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:45:57Z","timestamp":1777387557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-025-00797-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["797"],"URL":"https:\/\/doi.org\/10.1007\/s40271-025-00797-9","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Justin R. Abbatemarco and Devon S. Conway or their institutions have received compensation from research and funding organizations and\/or pharmaceutical companies for speaking, consulting, and\/or contracted research. Adrian Kielhorn, Jeffrey C. Yu, and Sami Fam are employees of Alexion, AstraZeneca Rare Disease, and hold stock or stock options in AstraZeneca. Kelley Myers and Christine Poulos are employees of RTI Health Solutions, which received funding from Alexion, AstraZeneca Rare Disease, to conduct this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Before pretesting, the survey was reviewed by the Institutional Review Board at Research Triangle Institute International (Research Triangle Park, NC, USA), which determined it to be exempt from full review on the basis of the level of risk and nature of the research (STUDY00022088).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All pretest participants provided informed consent. The project leader or their authorized designee conducted the informed consent process for the pretest interviews. Participants reviewed the informed consent and provided verbal consent before the pretest interview began. All online survey participants provided informed consent before entering the programmed survey. The informed consent for participating in the online survey was programmed for online administration.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Portions of the data reported here were presented as a poster at the American Academy of Neurology (AAN) Summer Conference, 19\u201320 July 2024, Atlanta, GA, USA, and were submitted as an abstract to the American Academy of Neurology (AAN) Annual Meeting, 5\u20139 April 2025, San Diego, CA, USA.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous presentation"}},{"value":"Conceptualization\u2014Kelley Myers, Christine M. Poulos, Justin R. Abbatemarco, and Devon S. Conway; data curation\u2014Kelley Myers; formal analysis\u2014Kelley Myers, Christine M. Poulos, and Justin R. Abbatemarco; investigation\u2014Kelley Myers and Justin R. Abbatemarco; methodology\u2014Kelley Myers, Christine M. Poulos, Justin R. Abbatemarco, and Devon S. Conway; project administration\u2014Kelley Myers; supervision\u2014Kelley Myers and Christine M. Poulos; critical review and approval of final version for submission\u2014Justin R. Abbatemarco, Adrian Kielhorn, Jeffrey C. Yu, Sami Fam, Kelley Myers, Devon\u00a0S. Conway, and Christine M. Poulos.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"Data will be made available to qualified investigators upon reasonable request to the corresponding author.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}